Innovations in Vascular Access Preparations
VentureMed Group, Inc., known for its groundbreaking medical device innovations, has been at the forefront of enhancing procedures related to arteriovenous (AV) access and peripheral arterial disease (PAD). During the recent Charing Cross Symposium, exciting data was unveiled that emphasizes the importance and effectiveness of the FLEX Vessel Prep™ System. This innovative system is not only designed to prepare vessels for interventions but also aims to optimize patient outcomes while minimizing potential complications.
Understanding the FLEX FIRST AV Registry
The FLEX FIRST AV Registry provides compelling insights into the performance of the FLEX Vessel Prep™ System over a six-month period. This observational study included 130 patients undergoing hemodialysis, all dealing with vascular access dysfunction. The primary investigator, Dr. Ari Kramer, shared invaluable insights into how the system has transformed his approach to treating stubborn stenoses.
A Paradigm Shift in Vascular Treatment
Dr. Kramer expressed his enthusiasm: "The FLEX VP System has revolutionized my approach to challenging stenoses. This study validates my observations—controlled micro-incisions bring about technical precision and significant clinical effectiveness in decreasing the need for reintervention. It marks a transition from the traditional, forceful dilation to a more refined, surgical-style technique that embodies precision endovascular medicine. Our patients deserve this level of care."
Key Findings from the Research
The registry's six-month results underscore the procedural safety and long-lasting effectiveness of the FLEX system in a real-world setting. Notable findings included:
- No serious adverse events reported through the one-month follow-up period.
- 70.7% primary patency for target lesions observed after six months.
- 76.3% patency in lesions located in the Cephalic Arch.
- Achieved 100% technical success in device delivery across all procedures.
Vessel Preparation and Angioplasty Outcomes
In addition to the FLEX FIRST AV Registry, additional data presented demonstrated how vessel preparation prior to drug-coated angioplasty can significantly enhance patency rates for hemodialysis vascular access. Dr. Robert Shahverdyan discussed his findings after utilizing the FLEX system in over 70 patients, comparing it against various techniques including high-pressure and scoring balloons.
Consistency in Results
Dr. Shahverdyan noted, "The results we've obtained with the FLEX system are consistently favorable across different types of access, lesion sites, and patient demographics. The rates of reintervention have substantially decreased, making FLEX my preferred choice for preparing resistant stenoses and reshaping our approach to access maintenance."
Impressive Outcomes with FLEX
His observations highlighted the significant benefits of using FLEX before drug-coated angioplasty, which included:
- Advanced target lesion primary patency (TLPP) rates at 86.0% after six months and 73.6% at 12 months.
- Lower reintervention rates, averaging 0.372 per patient-year in the VP group compared to 0.695 in POBA and 0.917 in scoring balloon groups.
- In Cephalic Arch interventions, 75% of patients maintained TLPP at 12 months, illustrating superior outcomes in this demographic.
The Future of Vascular Management with FLEX
Denis Harrington, President & CEO of VentureMed Group, expressed gratitude to Dr. Kramer and Dr. Shahverdyan for their dedication and praised their successful studies. This expanding body of evidence supports the proven efficacy of the FLEX Vessel Prep™ System. He emphasized, "Patients around the world, especially those relying on AV access, deserve state-of-the-art treatments and methodologies as demonstrated in our research efforts."
About VentureMed Group and FLEX Vessel Prep™ System
As a leader in medical device innovation, VentureMed Group, Inc. is committed to improving endovascular solutions for both AV access and peripheral arterial disease. The FLEX Vessel Prep™ System employs its proprietary Kinetic Endovascular Micro-incision Creation (KEMIC) technology to redefine how vessels are prepared. This method utilizes controlled movement to create precise micro-incisions, contrasting sharply with conventional balloon techniques. The result is improved drug uptake, reduced vessel trauma, and a lower risk of restenosis, promoting better long-term outcomes for patients.
Frequently Asked Questions
What is the FLEX Vessel Prep™ System?
The FLEX Vessel Prep™ System is a medical device designed to prepare blood vessels effectively for interventions, enhancing patient outcomes.
How does the FLEX system differ from traditional methods?
Unlike traditional balloons that apply static pressure, the FLEX system uses controlled motion to create precise micro-incisions, optimizing the preparation process.
What were the key findings from the FLEX FIRST AV Registry?
The registry showed significant results including 70.7% primary patency and no serious adverse events during the follow-up period.
Who is behind the FLEX Vessel Prep™ System?
VentureMed Group, Inc. is the company behind the FLEX system, known for its advancements in endovascular solutions.
What are the advantages of using FLEX before angioplasty?
Using FLEX prior to angioplasty can improve patency rates significantly and reduce the rates of reintervention.
